The 3P Laboratory (Pharmacokinetics (PK), Pharmacodynamics (PD) and Pharmacogenetics (PG)) was established by the UWCCC more than 25 years ago to support the translational and clinical research activities of our members. The mission of the 3P Laboratory is to advance cancer research by providing expertise;leadership;and bioanalytical assay development, validation and performance in support of the clinical, translational and laboratory research endeavors of UWCCC investigators. The 3P Lab provides UWCCC members with sample acquisition, processing, storage and shipping services for all PK/PD/PG clinical studies. It provides analysis of samples for PK/PD/PG studies in support of multiple NCI grants as well as research conducted by individual UWCCC investigators. In addition, the 3P Lab provides services for investigators in the preclinical setting to support new drug development. Services include generation of tumor xenografts for testing of investigational compounds, as well as evaluating plasma and intra-tumor drug levels in animal models. This service includes development and performance of original assays for new agents;assays to monitor endogenous biochemicals;and genotyping and mutation assays. Finally, the 3P Lab offers access to their bioanalytical instrumentation to trained UWCCC investigators.

Public Health Relevance

The 3P Laboratory (Pharmacokinetics, Pharmacodynamics and Pharmacogenetics) provides analytical support for biospecimens obtained in the clinical trials conducted at the University of Wisconsin Carbone Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA014520-39
Application #
8483727
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-04-25
Project End
2018-03-31
Budget Start
2013-04-12
Budget End
2014-03-31
Support Year
39
Fiscal Year
2013
Total Cost
$139,930
Indirect Cost
$66,048
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Rutter, Carolyn M; Kim, Jane J; Meester, Reinier G S et al. (2018) Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study. Cancer Epidemiol Biomarkers Prev 27:158-164
Jadvar, Hossein; Chen, Xiaoyuan; Cai, Weibo et al. (2018) Radiotheranostics in Cancer Diagnosis and Management. Radiology 286:388-400
Denu, Ryan A; Shabbir, Maria; Nihal, Minakshi et al. (2018) Centriole Overduplication is the Predominant Mechanism Leading to Centrosome Amplification in Melanoma. Mol Cancer Res 16:517-527
England, Christopher G; Jiang, Dawei; Ehlerding, Emily B et al. (2018) 89Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. Eur J Nucl Med Mol Imaging 45:110-120
Ong, Irene M; Gonzalez, Jose G; McIlwain, Sean J et al. (2018) Gut microbiome populations are associated with structure-specific changes in white matter architecture. Transl Psychiatry 8:6
Trentham-Dietz, Amy; Ergun, Mehmet Ali; Alagoz, Oguzhan et al. (2018) Comparative effectiveness of incorporating a hypothetical DCIS prognostic marker into breast cancer screening. Breast Cancer Res Treat 168:229-239
Weiss, Jennifer M; Pandhi, Nancy; Kraft, Sally et al. (2018) Primary care colorectal cancer screening correlates with breast cancer screening: implications for colorectal cancer screening improvement interventions. Clin Transl Gastroenterol 9:148
Bruce, Jordan G; Tucholka, Jennifer L; Steffens, Nicole M et al. (2018) Feasibility of Providing Web-Based Information to Breast Cancer Patients Prior to a Surgical Consult. J Cancer Educ 33:1069-1074
Huynh, Mailee; Pak, Chorom; Markovina, Stephanie et al. (2018) Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-?B activity and increases drug resistance in multiple myeloma. J Biol Chem 293:2452-2465
Wu, Yirong; Fan, Jun; Peissig, Peggy et al. (2018) Quantifying predictive capability of electronic health records for the most harmful breast cancer. Proc SPIE Int Soc Opt Eng 10577:

Showing the most recent 10 out of 1528 publications